NEAM
ANIK icon

New England Asset Management’s Anika Therapeutics ANIK Stock Holding History

New England Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-883
Closed -$37K – 169
2018
Q3 		$37K Hold
883
– – ﹤0.01% 214
2018
Q2 		$28K Buy
+883
New +$36.4K ﹤0.01% 215

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

New England Asset Management's ANIK Position: Q4 2018 in Review

New England Asset Management sold out of Anika Therapeutics (ANIK) in Q4 2018, closing a stake of 883 shares — an estimated $37K sold.

New England Asset Management first reported a position in ANIK in Q2 2018 and held it in 2 quarters. The position peaked at $37K in Q3 2018. 162 funds tracked by Wall St. Rank hold ANIK as of Q4 2018.

  • New England Asset Management reported no remaining Anika Therapeutics position as of Q4 2018 after selling out during the quarter.
  • New England Asset Management sold 883 Anika Therapeutics shares in Q4 2018, an estimated $37K.
  • New England Asset Management first reported a position in Anika Therapeutics in Q2 2018 and held it in 2 quarters.
  • New England Asset Management's Anika Therapeutics position peaked at $37K in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2018.

Based on New England Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.